Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Purchased by Northern Trust Corp

Northern Trust Corp raised its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 8.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 331,500 shares of the company’s stock after acquiring an additional 27,104 shares during the period. Northern Trust Corp owned approximately 0.68% of Enliven Therapeutics worth $7,459,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the business. Tower Research Capital LLC TRC lifted its position in shares of Enliven Therapeutics by 230.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock worth $36,000 after purchasing an additional 1,114 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Enliven Therapeutics during the fourth quarter valued at approximately $97,000. ExodusPoint Capital Management LP bought a new position in Enliven Therapeutics during the 4th quarter worth approximately $200,000. China Universal Asset Management Co. Ltd. lifted its holdings in Enliven Therapeutics by 14.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company’s stock worth $233,000 after buying an additional 1,275 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Enliven Therapeutics by 17.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,627 shares of the company’s stock worth $307,000 after acquiring an additional 1,980 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Performance

Shares of NASDAQ:ELVN opened at $16.85 on Tuesday. The firm has a 50 day simple moving average of $18.76 and a 200 day simple moving average of $21.58. Enliven Therapeutics, Inc. has a 52 week low of $13.30 and a 52 week high of $30.03. The company has a market cap of $826.81 million, a PE ratio of -8.87 and a beta of 1.07.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.06). On average, equities analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, COO Anish Patel sold 6,667 shares of the company’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $21.44, for a total transaction of $142,940.48. Following the completion of the sale, the chief operating officer now owns 323,310 shares in the company, valued at approximately $6,931,766.40. The trade was a 2.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Benjamin Hohl sold 3,250 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $20.41, for a total value of $66,332.50. Following the transaction, the chief financial officer now owns 13,000 shares in the company, valued at approximately $265,330. This trade represents a 20.00% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 76,111 shares of company stock worth $1,493,145. Insiders own 29.20% of the company’s stock.

Analysts Set New Price Targets

ELVN has been the topic of a number of research reports. HC Wainwright increased their target price on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, May 15th. Jones Trading lowered their price objective on shares of Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating for the company in a research report on Friday. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $37.25.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.